RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

• Main Authors: Takuo Hayashi (Author), Igor Odintsov (Author), Roger S. Smith (Author), Kota Ishizawa (Author), Allan J. W. Liu (Author), Lukas Delasos (Author), Christopher Kurzatkowski (Author), Huichun Tai (Author), Eric Gladstone (Author), Morana Vojnic (Author), Shinji Kohsaka (Author), Ken Suzawa (Author), Zebing Liu (Author), Siddharth Kunte (Author), Marissa S. Mattar (Author), Inna Khodos (Author), Monika A. Davare (Author), Alexander Drilon (Author), Emily Cheng (Author), Elisa de Stanchina (Author), Marc Ladanyi (Author), Romel Somwar (Author)
• Format: Book
• Published: The Company of Biologists, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms. Moreover, these inhibitors may have different efficacies agains...